(Q30982699)

28 June 2017

0 references

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (English)

1 reference

28 June 2017

0 references

0 references

0 references

1 reference

S Anderson

6

0 references

Richard Gray

object named as

R Gray

Early Breast Cancer Trialists' Collaborative Group

19

0 references

1

object named as

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

1 reference

ORCID Public Data File 2021

28 June 2017

1 reference

author name string

R Coleman

2

1 reference

28 June 2017

T Powles

3

1 reference

28 June 2017

A Paterson

4

1 reference

28 June 2017

M Gnant

5

1 reference

28 June 2017

I Diel

7

1 reference

28 June 2017

J Gralow

8

1 reference

28 June 2017

G von Minckwitz

9

1 reference

28 June 2017

V Moebus

10

1 reference

28 June 2017

J Bergh

11

1 reference

28 June 2017

K I Pritchard

12

1 reference

28 June 2017

J Bliss

13

1 reference

28 June 2017

D Cameron

14

1 reference

28 June 2017

V Evans

15

1 reference

28 June 2017

H Pan

16

1 reference

28 June 2017

R Peto

17

1 reference

28 June 2017

R Bradley

18

1 reference

28 June 2017

language of work or name

English

0 references

publication date

23 July 2015

1 reference

full work available at URL

28 June 2017

http://eprints.whiterose.ac.uk/91407

content deliverer

White Rose Research Online

object has role

published version

1 reference

White Rose Research Online

http://eprints.whiterose.ac.uk/91407

15 December 2018

1 reference

28 June 2017

volume

386

1 reference

28 June 2017

issue

10001

1 reference

28 June 2017

page(s)

1353-1361

1 reference

describes a project that uses

28 June 2017

meta-analysis

0 references

cites work

Cancer to bone: a fatal attraction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Mechanisms of bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Activation of γδ T cells by bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Clodronate decreases the frequency of skeletal metastases in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Breast-cancer adjuvant therapy with zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Effects of bone-targeted agents on cancer progression and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Oral bisphosphonate use and breast cancer incidence in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Use of bisphosphonates and risk of postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Bone turnover across the menopause transition : The role of gonadal inhibins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960908-4

7 January 2021

10.1016/S0140-6736(15)60908-4

Identifiers

DOI

1 reference

10.1016/S0140-6736(15)60908-4

28 June 2017

Altmetric DOI

0 references

CORE ID

90681768

0 references

Dimensions Publication ID

1043267983

0 references

1 reference